论文部分内容阅读
目的分析局部注射和肝动脉给予血管抑素基因(Angiostatin)和内皮抑素基因(Endostatin)重组质粒对大鼠肝癌治疗效果的差异。方法将肝癌模型大鼠随机分为:局部治疗组、局部对照组、肝动脉治疗组、肝动脉对照组。治疗组给予200μL质粒和脂质体复合物和对照组给予生理盐水200μL。治疗后观测肿瘤大小、微血管密度、血管内皮生长因子、肿瘤凋亡指标的变化。结果6d开始基因治疗组各治疗指标与对照组相比均具有统计学差异,(P<0.05-0.001)。局部治疗组与肝动脉治疗组相比也具有统计学意义,(P<0.05-0.01)。结论本研究的结果显示,重组质粒两种方式对于肝癌均有抑制效果,但肝动脉的抑瘤效果不如局部注射,主要与重组质粒进入肿瘤方式不同有关。
Objective To analyze the therapeutic effect of Angiostatin and Endostatin recombinant plasmids administered by local injection and hepatic artery on rat liver cancer. Methods The liver cancer model rats were randomly divided into local treatment group, local control group, hepatic artery treatment group and hepatic artery control group. The treatment group received 200 μL of plasmid and liposome complex and the control group received 200 μL of physiological saline. After treatment, the changes of tumor size, microvessel density, vascular endothelial growth factor and tumor apoptosis index were observed. Results At the 6th day, the therapeutic indexes in gene therapy group were statistically different from those in control group (P <0.05-0.001). Local treatment group and hepatic artery treatment group also had statistical significance (P <0.05-0.01). Conclusions The results of this study showed that both recombinant plasmids could inhibit the growth of HCC. However, the anti-tumor effect of hepatic artery was not as good as that of local injection, which was mainly related to the different ways of entering the tumor by recombinant plasmids.